Layaisa

Drospirenone/Ethinylestradiol, the active ingredient in Layaisa, is a combined oral contraceptive presented as a tablet for oral use. It works by inhibiting ovulation and creating cervical‑mucus changes that prevent fertilization, providing reliable pregnancy prevention for women of reproductive age.

GNH USA supplies Layaisa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets through robust supply‑chain management and adherence to EU manufacturing standards.

Layaisa, a combined oral contraceptive, is indicated for hormonal contraception to prevent pregnancy.

- Prevention of pregnancy: provides reliable contraceptive protection for women of childbearing potential. - Regulation of menstrual cycles: helps achieve more predictable bleeding and reduces menstrual flow. - Treatment of moderate acne: hormonal modulation can improve acne in women.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like. - Breast tenderness: transient swelling or discomfort. - Weight gain: modest fluid retention. - Mood changes: irritability or mild depression. - Spotting or breakthrough bleeding: irregular light bleeding.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins. - Pulmonary embolism: clot migration to lungs. - Stroke: cerebrovascular accident. - Myocardial infarction: heart attack. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Liver dysfunction: jaundice or elevated enzymes.

Before prescribing Layaisa, clinicians should consider the following precautions: - Thromboembolic risk assessment: evaluate personal or family history of clotting disorders. - Hepatic function review: avoid use in active liver disease. - Smoking status: contraindicated in women >35 who smoke. - Missed pill counseling: advise on appropriate backup contraception. - Pregnancy avoidance: ensure patient is not pregnant before initiation. - Store at below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Layaisa may interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce contraceptive efficacy. - Certain antiretrovirals (e.g., efavirenz): may lower hormone levels. - St. John’s wort: decreases plasma concentrations. - Griseofulvin: reduces oral contraceptive effectiveness. - Protease inhibitors (e.g., ritonavir): unpredictable hormonal exposure.

Moderate Interactions (Monitor Closely): - Antifungals (ketoconazole, itraconazole): may increase hormone levels. - SSRIs (e.g., fluoxetine): modest effect on metabolism. - Diuretics (e.g., hydrochlorothiazide): may alter fluid balance. - Antihypertensives (e.g., ACE inhibitors): watch for blood‑pressure changes. - Herbal supplements (e.g., ginseng): potential mild interaction.